Larimar Therapeutics
NEWS
Despite tolerability concerns, nomlabofusp’s overall efficacy represents a “large win” for Larimar, according to analysts at William Blair, who lauded the therapy’s functional benefits.
Phase II data indicate Larimar Therapeutics’ injectable therapy nomlabofusp could go head-to-head in the market with Biogen’s Skyclarys.
BioSpace spoke with four veterans in the field about the less obvious reasons why companies with good science may still fail.
This is after Larimar reported deaths in the highest dose levels of a nonhuman primate toxicology study.
IN THE PRESS
JOBS